Table 4.
Characteristics and outcomes for patients who completed the exit interview—Southern Malawi, 2015
| n/N | Weighted percent (95% CI) | |
|---|---|---|
| Demographics (years) | ||
| <5 | 723/2342 | 28.3 (21.8, 34.8) |
| ≥5 | 1619/2342 | 71.7 (65.2, 78.2) |
| Suspect malaria classification | ||
| Suspect malaria cases (both uncomplicated and severe) | 1695/2342 | 73.4 (70.2, 76.6) |
| Suspect uncomplicated malaria | 1605/1695 | 95.4 (94.2, 96.6) |
| Suspect severe malaria | 90/1695 | 4.6 (3.4, 5.8) |
| Symptoms spontaneously reported to HW by suspect malaria patients | ||
| Fever | 1146/1695 | 68.5 (64.0, 73.0) |
| When patient did not spontaneously report fever, HW asked about fever | 295/549 | 51.6 (46.0, 57.2) |
| Headache | 553/1695 | 33.4 (28.6, 38.2) |
| Vomiting | 284/1695 | 16.9 (14.3, 19.5) |
| Skin problem | 99/1695 | 5.5 (3.9, 6.9) |
| Testing for suspect uncomplicated malaria patients who attended HFs with diagnostic tests | ||
| Tested by either microscopy or RDT | 1072/1427 | 75.7 (68.9, 82.5) |
| Positive RDT or microscopy | 547/1072 | 53.2 (46.0, 60.4) |
| Medications administered, prescribed or dispensed to confirmed uncomplicated malaria patients | ||
| Treated with first- or second-line antimalarial (AM)a | 511/547 | 92.7 (85.4, 99.9) |
| Treated with other anti-malarialb | 12/547 | 4.7 (0.0, 11.9) |
| No anti-malarial | 24/547 | 2.6 (1.2, 4.0) |
| Medications administered, prescribed or dispensed to presumed uncomplicated malaria patients | ||
| Treated with first- or second-line AMa | 98/178 | 60.3 (45.1, 75.5) |
| Treated with other anti-malarialc | 5/178 | 2.8 (0.0, 8.3) |
| No anti-malarial | 75/178 | 36.8 (22.8, 50.8) |
| Suspect severe malaria | ||
| Received recommended pre-referral anti-malariald | 8/90 | 5.7 (0.3, 11.0) |
| Referred or told to get in-patient admission right away | 11/90 | 6.9 (1.9, 11.9) |
| Received pre-referral anti-malarial plus immediate referral/admission | 3/90 | 1.6 (0.0, 3.6) |
| Treated with other anti-malariale | 46/90 | 59.6 (46.4, 72.8) |
| No anti-malarial | 36/90 | 34.7 (22.4, 47.0) |
aFirst- or second-line AM refers to artemether-lumefantrine (AL) or artesunate-amodiaquine (ASAQ) for all except pregnant women in first trimester and children weighing <5 kg who get quinine. Numerator includes eight confirmed malaria patients who got both AL and intramuscular (IM) quinine and one confirmed malaria patient who got both AL and IM artesunate
bOral quinine (n = 6), IM quinine (n = 3), AL to women in first trimester (n = 2), SP (n = 1)
cAll given sulfadoxine-pyrimethamine (SP) none of whom was pregnant
dThree received IM artesunate, five received IM quinine
e42 patients received only AL, one received both AL and SP, one received ASAQ and two received oral quinine